Literature DB >> 8285633

Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.

R A Zabinski1, K Vance-Bryan, A J Krinke, K J Walker, J A Moody, J C Rotschafer.   

Abstract

An in vitro pharmacodynamic system has been successfully adapted to simulate in vivo antimicrobial pharmacokinetics under anaerobic conditions. This system was used to perform time-kill kinetic studies which were designed to compare the activity of temafloxacin to ciprofloxacin and cefotetan against two strains of Bacteroides fragilis (ATCC 25285 and ATCC 23745). All experiments were performed as single-dose, 24-h, duplicate runs. Starting bacterial inocula of 10(7) CFU/ml were exposed to starting antimicrobial concentrations of 5 micrograms of temafloxacin per ml, 5 micrograms of ciprofloxacin per ml, and 100 micrograms of cefotetan per ml. Terminal half-lives of 8, 4, and 4 h were simulated for each antimicrobial agent. Temafloxacin was rapidly bactericidal against B. fragilis. Ciprofloxacin was not bactericidal (< 3 log10 unit decline in bacterial numbers) to either strain of B. fragilis. Cefotetan was bactericidal (> or = 3 log10 unit decline in bacterial numbers) to each strain but killed at a slower rate than temafloxacin. Times to 3 log10 unit declines of strain ATCC 25285 were 2, 4, and > 24 h, whereas those of strain ATCC 23745 were 4, 4, and > 24 h for temafloxacin, cefotetan, and ciprofloxacin, respectively. Total logarithmic declines of strain ATCC 25285 were > 4.5, > 4.5, and 2.9 log10 CFU/ml, whereas those of strain ATCC 23745 were 4.1, > 4.5, and 1.2 log10 CFU/ml for each drug, respectively. These and other studies demonstrated that temafloxacin showed potential as an agent that could have been further developed for use in the treatment of anaerobic infections. However, the drug was removed from the market by its manufacturer because of toxicity issues. Although the release of newer fluoroquinolones that possess significant activity against anaerobic bacteria does not appear imminent, the time-kill studies performed in this study demonstrate that further research is warranted in the development of fluoroquinolones which possess significant antianaerobic activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8285633      PMCID: PMC192408          DOI: 10.1128/AAC.37.11.2454

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.

Authors:  K Nye; Y G Shi; J M Andrews; J P Ashby; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

3.  Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies.

Authors:  C W Stratton; L S Weeks
Journal:  Diagn Microbiol Infect Dis       Date:  1990 May-Jun       Impact factor: 2.803

4.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

5.  Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

6.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model.

Authors:  A U Gerber; A P Vastola; J Brandel; W A Craig
Journal:  J Infect Dis       Date:  1982-11       Impact factor: 5.226

8.  Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection.

Authors:  M N Dudley; J Blaser; D Gilbert; K H Mayer; S H Zinner
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

9.  Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.

Authors:  B J McGrath; E M Bailey; K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more
  14 in total

Review 1.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Authors:  David H Wright; Brent W Gunderson; Laurie B Hovde; Gigi H Ross; Khalid H Ibrahim; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.

Authors:  Lisa A Kroeger; Laurie B Hovde; Isaac F Mitropoulos; Jeremy Schafer; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

4.  Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.

Authors:  M L Peterson; L B Hovde; D H Wright; G H Brown; A D Hoang; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.

Authors:  Alan R Noel; Karen E Bowker; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.

Authors:  Reiner Schaumann; Matthias Funke; Eva Janssen; Arne C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

7.  A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; Y A Portnoy; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.

Authors:  K J Madaras-Kelly; B E Ostergaard; L B Hovde; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

Authors:  Brent W Gunderson; Khalid H Ibrahim; Charles A Peloquin; Laurie B Hovde; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.

Authors:  R A Zabinski; K J Walker; A J Larsson; J A Moody; G W Kaatz; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.